STIM Neuronetics

Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via webcast at . To listen to the conference call on your telephone, participants may register for the call . While it is not required, it is recommended you join 10 minutes prior to the event start.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 7.1 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, .

Investor Contact:

Mike Vallie or Mark Klausner

ICR Healthcare

443-213-0499

Media Contact:

EvolveMKD

646-517-4220



EN
22/04/2025

Underlying

STIMNeuronetics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neuronetics

 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Launches First Inaugural National TMS Therapy Awareness Da...

Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that highlight the impact NeuroStar has as a safe, effective, and non-drug treatment for depression MALVERN, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision ...

May 14, 2025 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Reports First Quarter 2025 Financial and Operating Results

Neuronetics Reports First Quarter 2025 Financial and Operating Results MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2025. First Quarter 2025 Highlights First quarter 2025 revenue of $32.0 million, an 84% incr...

May 6, 2025 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 4,500 shares of the Company’s common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards ...

May 5, 2025 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics to Report First Quarter 2025 Financial and Operating Resul...

Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conf...

April 22, 2025 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Cov...

Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression Policy update increases access for millions covered by Evernorth Health Services MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, announced that Evernorth Health Services, a wholly owned subsidiary of T...

March 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch